复方伊维菌素、芬苯哒唑粉剂的研制及疗效试验
|
摘要
随着我国养殖业的集约化方向的发展,寄生虫病给养殖业带的经济损失越来越大,并且寄生虫的耐药性也不断被发现。为开发一种广谱(能驱除体内和体外寄生虫)、耐药性低、使用便利的复方制剂驱杀养殖业中的寄生虫混合感染。本研究以伊维菌素(Ivemectin)和芬苯哒唑(Fenbendazole)为原料,大豆油为稳定剂,碳酸钙、淀粉等为辅料,配制而成一系列粉剂,通过以下几个方面的研究,成功研制出复方伊维菌素粉剂。
1、本文采用6个月加温加湿试验和10天光加速试验对复方伊维菌素粉剂进行了稳定性研究。
2、本文中采用高效液相色谱法(HPLC-UV)测定复方伊维菌素粉剂的含量,伊维菌素在70～130μg·ml~(-1)浓度范围内与峰面积呈现良好线性关系,相关系数r=0.9952,(n=7);芬苯哒唑在70～130μg·ml~(-1)浓度范围内与峰面积呈现良好线性关系,相关系数r=0.9867,(n=7)。加温加湿试验6个月末和光加速试验第10天的结果表明伊维菌素和芬苯哒唑的相对标示量均在90%以上。所有参试样品的外观色泽、粒度、分解产物等指标均无明显变化。试验结果表明:该制剂稳定性良好。
3、疗效试验结果表明,加入伊维菌素复配芬苯哒唑后提高了产品的疗效,增宽了抗虫谱。临床疗效试验结果表明本制剂对常见动物各种体内外寄生虫均有良好的疗效,比二者的单方制具有更强的驱虫效果,经济性和适用更强。
综上所述,本文试验成功研制出复方伊维菌素—芬苯哒唑粉剂,同时对它的稳定性和临床治疗效果进行了研究。试验证明该制剂稳定性好,工艺简单,应用广泛;该制剂质量标准的建立表明标准方法具有稳定性强、可靠性好、分离度高的特点。临床试验结果表明,本制剂对动物常见的体内外寄生虫均有强大的杀灭作用,使用疗程足够有利于杀虫和减少耐药虫株的出现。
With the development of aquaculture industry in our country, Increasingly focused on breeding,inter-borne parasitic diseases, annual economic losses of aquaculture industry can not be ignored every year,according to Statistics:drug prevention and treatment of parasitic diseases accounted for the total farm dosage of 42.7%.With the widely uses of Vermifuges of aquaculture industry in our country,the drug resistance of parasites become increasingly serious. The development of a broad-spectrum(to get rid of parasites in vivo and in vitro),low resistance,convenient in use of the compound preparation has become immediate needs.The purpose of this study is select different mechanism of pesticides ivermectin and albendazole benzene tdazole fun as the main raw materials,develop an easy-to-use,broad spectrum insect repellent medicine.In this paper, ivermectin(Ivemectin) pyridaben benzene and triazole-fen (Fenbendazole) for raw materials,soya bean oil as a stabilizer,calcium carbonate,starch,such as accessories,from a series of powder preparation,through the following aspects of the study,successfully developed the compound powder of Ivermectin.
In this paper,6 months humidification heating test and accelerated test of 10days sky Ivermectin are be take to research the Stability of the Compound powder.
In this paper,we use high-performance liquid chromatography (HPLC-UV) to determint the content of the compound powder of ivermectin,ivermectin in 140～260μg·ml~(-1) concentration range with the peak area showed good linear relationship,correlation coefficient r=0.9952,(n=7),fenbendazole in the 70～130μg·ml~(-1) concentration range with the peak area showed good linear relationship,correlation coefficient r=0.9857,(n=7).The results of Humidification test heating and light at the end of 6 months and accelerated test at the first 10 days show that the relative marked of ivermectin and fenbendazole are more than 90%in both.Tested samples of all the appearance of color, grain size,and other indicators of decomposition products did not change significantly.The results showed that:the stability of the preparation is good.
Clinical trial results show that ivermectin-fun mix of fenbendazole can improve product efficacy,increased the efficacy of a wider spectrum of insect-resistant.The results show that the clinical efficacy of this preparation on a variety of common animal parasites in vitro and in vivo effects are good,than a unilateral system of the two is more repellent effect,and the application of a stronger economy.
To sum up,this article developed a compound ivermectin successfenbendazole powder,at the same time its stability and clinical therapeutic effects were studied.Tested the stability of the preparation, and process is simple,widely used;quality standards for the preparation of the establishment of standard methods show that it is shtability,reliability,and high isolation characteristics.Clinical trial results indicate that the preparation of the animals common both in vivo and in vitro parasite killing a powerful role,the use of pesticides in favor of adequate treatment and reduce the emergence of drug-resistant strains of insects.
1、本文采用6个月加温加湿试验和10天光加速试验对复方伊维菌素粉剂进行了稳定性研究。
2、本文中采用高效液相色谱法(HPLC-UV)测定复方伊维菌素粉剂的含量,伊维菌素在70～130μg·ml~(-1)浓度范围内与峰面积呈现良好线性关系,相关系数r=0.9952,(n=7);芬苯哒唑在70～130μg·ml~(-1)浓度范围内与峰面积呈现良好线性关系,相关系数r=0.9867,(n=7)。加温加湿试验6个月末和光加速试验第10天的结果表明伊维菌素和芬苯哒唑的相对标示量均在90%以上。所有参试样品的外观色泽、粒度、分解产物等指标均无明显变化。试验结果表明:该制剂稳定性良好。
3、疗效试验结果表明,加入伊维菌素复配芬苯哒唑后提高了产品的疗效,增宽了抗虫谱。临床疗效试验结果表明本制剂对常见动物各种体内外寄生虫均有良好的疗效,比二者的单方制具有更强的驱虫效果,经济性和适用更强。
综上所述,本文试验成功研制出复方伊维菌素—芬苯哒唑粉剂,同时对它的稳定性和临床治疗效果进行了研究。试验证明该制剂稳定性好,工艺简单,应用广泛;该制剂质量标准的建立表明标准方法具有稳定性强、可靠性好、分离度高的特点。临床试验结果表明,本制剂对动物常见的体内外寄生虫均有强大的杀灭作用,使用疗程足够有利于杀虫和减少耐药虫株的出现。
With the development of aquaculture industry in our country, Increasingly focused on breeding,inter-borne parasitic diseases, annual economic losses of aquaculture industry can not be ignored every year,according to Statistics:drug prevention and treatment of parasitic diseases accounted for the total farm dosage of 42.7%.With the widely uses of Vermifuges of aquaculture industry in our country,the drug resistance of parasites become increasingly serious. The development of a broad-spectrum(to get rid of parasites in vivo and in vitro),low resistance,convenient in use of the compound preparation has become immediate needs.The purpose of this study is select different mechanism of pesticides ivermectin and albendazole benzene tdazole fun as the main raw materials,develop an easy-to-use,broad spectrum insect repellent medicine.In this paper, ivermectin(Ivemectin) pyridaben benzene and triazole-fen (Fenbendazole) for raw materials,soya bean oil as a stabilizer,calcium carbonate,starch,such as accessories,from a series of powder preparation,through the following aspects of the study,successfully developed the compound powder of Ivermectin.
In this paper,6 months humidification heating test and accelerated test of 10days sky Ivermectin are be take to research the Stability of the Compound powder.
In this paper,we use high-performance liquid chromatography (HPLC-UV) to determint the content of the compound powder of ivermectin,ivermectin in 140～260μg·ml~(-1) concentration range with the peak area showed good linear relationship,correlation coefficient r=0.9952,(n=7),fenbendazole in the 70～130μg·ml~(-1) concentration range with the peak area showed good linear relationship,correlation coefficient r=0.9857,(n=7).The results of Humidification test heating and light at the end of 6 months and accelerated test at the first 10 days show that the relative marked of ivermectin and fenbendazole are more than 90%in both.Tested samples of all the appearance of color, grain size,and other indicators of decomposition products did not change significantly.The results showed that:the stability of the preparation is good.
Clinical trial results show that ivermectin-fun mix of fenbendazole can improve product efficacy,increased the efficacy of a wider spectrum of insect-resistant.The results show that the clinical efficacy of this preparation on a variety of common animal parasites in vitro and in vivo effects are good,than a unilateral system of the two is more repellent effect,and the application of a stronger economy.
To sum up,this article developed a compound ivermectin successfenbendazole powder,at the same time its stability and clinical therapeutic effects were studied.Tested the stability of the preparation, and process is simple,widely used;quality standards for the preparation of the establishment of standard methods show that it is shtability,reliability,and high isolation characteristics.Clinical trial results indicate that the preparation of the animals common both in vivo and in vitro parasite killing a powerful role,the use of pesticides in favor of adequate treatment and reduce the emergence of drug-resistant strains of insects.
引文
[1]夏立照.中国寄生虫病流行概况[J].安徽医科大学学报,2000,1:35
[2]陈杖榴.我国新兽药研发的思考[J].中国动物保健品行业发展年会,2003,1:32-35
[3]李毅斌.绵羊注射伊维菌素中毒与治疗[J].动物科学与动物医学,2003,2:15
[4]朱模忠主编.兽药手册[M].北京:中国农业出版社,1995:156
[5]中国兽药典委员会编.中华人民共和国兽药典[M].北京:中国农业出版社,2005,1:78-92
[6]蒋才武.广西师范学报[M].1999,5:13
[7]胡秀荣.伊维菌素晶体结构的研究[J].药学学报,1998,33:25-28
[8]刘海主编.动物常用药物及科学配伍手册[M].山东科学技术出版社,2008,1:125
[9]中国兽药典委员会编.兽药使用指南[M].北京:中国农业出版社,2006,1:116-129
[10]李有业.寄生虫对伊维菌素的抗药性及其应对措施[J].兽药与饲料添加剂,2003,8:18
[11]中国兽药典委员会编.兽药手册[M].北京:中国农业出版社,1994,2:127;143
[12]大环内酯类抗寄生虫研究进展[J].中国食品产业网。
[13]张剑英编著,鱼类寄生虫与寄生虫病[M].北京科学出版社,1999,2:65
[14]刘明春.伊维菌素的研究进展及其在兽医临床中的应用[J].辽宁畜牧兽医,2001,4:17-18
[15]Bogitsh BJ.Cheng TC:Human Parasitology.2nd ed.USA:Academic Press,1998;
[16]汪明.国产伊维菌素对绵羊消化道线虫的驱虫试验[J].中国兽医科技,1996,1:12-15
[17]韩博.国产伊维菌素口服液对绵羊寄生虫的驱除试验[J].中国兽医杂志,1997, 4:8-9
[18]方悦怡.伊维菌素和阿苯哒唑伍用驱除肠道线虫感染的效果观察[J].中国寄生虫病防治杂志,2003,16,4:33-35。
[19]陈小军.伊维菌素制剂在动物医学中的研究进展[J].湖南畜牧兽医,2005,1:12-13
[20]解留柱.应用阿维菌素、伊维菌素驱虫的几点体会[J].江西畜牧兽医杂志,2000,3:9-10
[21]杨绍基.蠕虫蚴移行症的诊断和治疗[J].新医学,2005,7:21
[22]吴中兴等.伊维菌素的药理、药效和临床研究[J].热带病与寄生虫学,2003,1,3:18
[23]郭建强.伊维菌素对台湾乳白蚁和黄胸散白蚁的毒性观察[J].中国媒介生物学及控制杂志,2005,16,4:45-48
[24]中国兽药典委员会编.兽药质量标准[M].北京:中国农业出版社,2003:57-58
[25]中国兽药典委员会编.进口兽药使用指导[M].北京:中国农业出版社,1995:53-54
[26]Markell JK:Medical Parasitology.8th ed.Philadephia:W.B.Saunders Company,1999.
[27]Gerald D.Schmidt,LarryS.Roberts.Foundations of parasitology.St.Louis:Times Mirror.Mosby College Pub.,1989
[28]NOAH.Fact and Figures Abautthe UK Animal Medicines Industry(2002)
[29]Chen-Sujen.Wang-Chingho,Chen-SJ,Wang-CH.Short comnunication:drug susceptibilityof pathogenic,strains of Escherichia Coli isolated from chickens between 1991 and1995.Journal of the Chinese Society of veterivnary-Science.1997 123:2,89-94
[30]Nosanchuk JS.Wade SE,Landolf M.Case report of and description of parasite in Mammomonogamus laryngeus(human syngamosis) infection.J Clin Microbiol,1995;33:998
[31] Gubler, DJ. Perspectives on the prevention and control of dengue hemorrhagic fever. Kaohsiung J Med Sci 1994; 10 : 15-18.
[32] Lim LH. Research on dengue vector. Kaohsiung J Med Sci 1994; 10 :116-119.
[33] Chunsuttiwat S, Wasakarawa S. Dengue vector control in Thailand: development towards environmental protection. Kaohsiung J Med Sci 1994; 10 : 122-123.
[34]WHO. Dengue hemorrhagic fever: diagnosis, treatment and control. Geneva:1986:1-2.
[35] Ministry of Health, Malaysia. Vector borne disease control program. Kaohsiung J Med Sci 1994;10 : 113-115.
[36] Dominguez NN. National dengue prevention and control program in the Philippines.Kaohsiung J Med Sci 1994; 10: 118-121.
[37] Soedarmo SP. The epidemiology prevention and control of dengue hemorrhagic fever in Indonesia. Kaohsiung J Med Sci 1994; 10 : 109-112.
[38] Wang NC. Control of dengue vector in Singapore. Kaohsiung J Med Sci 1994; 10 133-38.
[39] Nguyen HT, et al. Dengue/dengue hemorrhagic fever situation in Vietnan. Kaohsiung J Med Sci 1994;10 : 124-130.
[40] Umenai T, Suzuki H. Review of the dengue/dengue hemorrhagic fever situation in the Western Pacific Region. Dengue Newsletter 1987; 13 : 69.
[41] Do M, et al. Epidemiology of dengue hemorrhagic fever in Vietnan during 1975-1983. Dengue Newsletter 1985;11 : 89.
[42] WHO. Dengue and dengue haemorrhagic fever. South-East Asia Region.Wkly Epidem Rec 1986; 61(27) : 205.
[43] Ungchusak K, Kunasol P. DHF in Thailand: The worsening situation in 30 years. Dengue Newsletter 1987; 13: 63.
[44] WHO. Report of the Consultation. Key issues in dengue vector control toward operationalization of a global strategy.Geneva:1995:1.
[45]沈海令,赵志梅,金东虎等.比翼线虫肺内感染3例[J].延边大学医学院学报,1998;21(2):122
[46]孙成斋.肝吸虫病[J].沈阳药科大学学报,沈阳:科学技术出版社,1985,12:16
[47]卫生部卫生防疫司寄生虫病处.我国主要寄生虫病防治现状[J],1992:32
[48]李秉正.华支睾吸虫与华支睾吸虫病[M].辽宁:沈阳出版社,1997,1:78
[49]华湘津.华支睾吸虫病诊断研究进展[J],中国寄生虫学与寄生虫病杂志,1994,12(1).
[50]桂爱芳.快速滤纸干血—ELISA诊断华支睾吸虫病的价值[J],中国人兽共患病杂志,1993,9(6):48.
[51]宁安等.华支睾吸虫病防治措施的研究[J].中国寄生虫病防治杂志,1994,7(4):52.
[52]胡秀荣、顾建明、陈林深、皇甫永令等.伊维菌素(1vermectin)晶体结构的研究[J].药学学报.1998.33(6):449-452
[53]杨明瑾.伊维菌素对大白鼠的长期毒性试验的研究[J].浙江省医学科学院学报,2000,6:45
[54]李明成.伊维菌素类药物的耐药性[J].黑龙江畜牧兽医.2001,9:19
[55]刘群.紫外分光光度法测定伊维菌素预混剂的含量.兽药与饲料添加剂.2001,6:15-18
[56]雷荣.高效液相色谱—串联质谱法鉴定伊维菌素的成分.分析化学研究报告.2002,1:29-32
[57]李毅斌.绵羊注射伊维菌素的中毒与治疗.动物科学与动物医学.2003,2,20(2):35
[58]徐慧斌,沈杰,叶明忠等.阿维菌素长效控释丸在绵羊体内的药物动力学研究[J].中国兽医寄生虫病杂志.1996,4(2):4-7
[59]王颜军.伊维菌素0.2%预混剂治疗蛋鸡皮刺螨效果观察[J].中国兽医杂志,2002,3:27
[60]冯克清.高效液相色谱法测定芬苯达唑原料中的有关物质[J].中国兽药杂志,2004,38(11):19-21
[61]许正敏.芬苯达唑、氟苯达唑和阿苯达唑对隐藏管状线虫作用的观察[J].中国寄生虫病防治杂志Chinese Journal of Parasitic D isease Control 1998;l1(1)
[62]李福荣.吡喹酮脂质体、吡喹酮、阿苯哒唑、氟苯哒唑和甲苯哒唑对胞球蚴病的疗效观察[J].中国寄生虫防治杂志,1995,8(1):39
[63]杨光友.丙硫苯咪唑和吡喹酮对鸭人工感染台湾次睾吸虫的驱除试验[J].中国兽医杂志,2004,3:15-16
[64]任丽君.伊维菌素缓释注射液的制备、含量测定及药代动力学[J].新缰医科大学硕士学位论文,2003:45-48
[65]郭虹,陈观今,郑焕钦等.弓形虫ROPI真核表达重组质粒DNA免疫小鼠后的免疫应答[J].中国寄生虫病与寄生虫病杂志,1999,175001-5004.
[66]杨维平,吴中兴.人体寄生虫病化学药物防治[M].南京:东南大学出版社,2004,
[67]冯忠武.我国兽药行业发展的现状及展望[J].中国兽药杂志,2004,38(3):1-6.
[68]莫云.简析跨国企业的兽药产品及市场特点[J].中国动物保健,2003,10:40-42.
[69]严晓岗.伊维菌素一般药理实验[J],浙江省医学院学报,2003,3:45
[70]刘明春.伊维菌素研究进展及其在我国兽医临床中的应用[J],辽宁畜牧畜医,2001,8:12
[71]张宏伟/杨廷桂主编,动物寄生虫病[M].中国农业出版社,2006,2:195
[72]沈继龙主编.医学寄生虫学[M].北京:中国医药科技出版社,1992,2:216
[73]古钦民主编.人体寄生虫学[M].青岛:青岛海洋大学出版社,1996,3:214
[74]詹希美主编.人体寄生虫学[M].第五版.北京:人民卫生出版社,2001,3:56
[75]詹希美主编.人体寄生虫学[M].北京:人民卫生出版社,2001,1:98
[76]陈兴保主编.现代寄生虫病学[M].北京:人民军医出版社,2002,1:105
[77]殷国荣主编.医学寄生虫学[M].双语教学版.北京:科学出版社,2004,1:563
[2]陈杖榴.我国新兽药研发的思考[J].中国动物保健品行业发展年会,2003,1:32-35
[3]李毅斌.绵羊注射伊维菌素中毒与治疗[J].动物科学与动物医学,2003,2:15
[4]朱模忠主编.兽药手册[M].北京:中国农业出版社,1995:156
[5]中国兽药典委员会编.中华人民共和国兽药典[M].北京:中国农业出版社,2005,1:78-92
[6]蒋才武.广西师范学报[M].1999,5:13
[7]胡秀荣.伊维菌素晶体结构的研究[J].药学学报,1998,33:25-28
[8]刘海主编.动物常用药物及科学配伍手册[M].山东科学技术出版社,2008,1:125
[9]中国兽药典委员会编.兽药使用指南[M].北京:中国农业出版社,2006,1:116-129
[10]李有业.寄生虫对伊维菌素的抗药性及其应对措施[J].兽药与饲料添加剂,2003,8:18
[11]中国兽药典委员会编.兽药手册[M].北京:中国农业出版社,1994,2:127;143
[12]大环内酯类抗寄生虫研究进展[J].中国食品产业网。
[13]张剑英编著,鱼类寄生虫与寄生虫病[M].北京科学出版社,1999,2:65
[14]刘明春.伊维菌素的研究进展及其在兽医临床中的应用[J].辽宁畜牧兽医,2001,4:17-18
[15]Bogitsh BJ.Cheng TC:Human Parasitology.2nd ed.USA:Academic Press,1998;
[16]汪明.国产伊维菌素对绵羊消化道线虫的驱虫试验[J].中国兽医科技,1996,1:12-15
[17]韩博.国产伊维菌素口服液对绵羊寄生虫的驱除试验[J].中国兽医杂志,1997, 4:8-9
[18]方悦怡.伊维菌素和阿苯哒唑伍用驱除肠道线虫感染的效果观察[J].中国寄生虫病防治杂志,2003,16,4:33-35。
[19]陈小军.伊维菌素制剂在动物医学中的研究进展[J].湖南畜牧兽医,2005,1:12-13
[20]解留柱.应用阿维菌素、伊维菌素驱虫的几点体会[J].江西畜牧兽医杂志,2000,3:9-10
[21]杨绍基.蠕虫蚴移行症的诊断和治疗[J].新医学,2005,7:21
[22]吴中兴等.伊维菌素的药理、药效和临床研究[J].热带病与寄生虫学,2003,1,3:18
[23]郭建强.伊维菌素对台湾乳白蚁和黄胸散白蚁的毒性观察[J].中国媒介生物学及控制杂志,2005,16,4:45-48
[24]中国兽药典委员会编.兽药质量标准[M].北京:中国农业出版社,2003:57-58
[25]中国兽药典委员会编.进口兽药使用指导[M].北京:中国农业出版社,1995:53-54
[26]Markell JK:Medical Parasitology.8th ed.Philadephia:W.B.Saunders Company,1999.
[27]Gerald D.Schmidt,LarryS.Roberts.Foundations of parasitology.St.Louis:Times Mirror.Mosby College Pub.,1989
[28]NOAH.Fact and Figures Abautthe UK Animal Medicines Industry(2002)
[29]Chen-Sujen.Wang-Chingho,Chen-SJ,Wang-CH.Short comnunication:drug susceptibilityof pathogenic,strains of Escherichia Coli isolated from chickens between 1991 and1995.Journal of the Chinese Society of veterivnary-Science.1997 123:2,89-94
[30]Nosanchuk JS.Wade SE,Landolf M.Case report of and description of parasite in Mammomonogamus laryngeus(human syngamosis) infection.J Clin Microbiol,1995;33:998
[31] Gubler, DJ. Perspectives on the prevention and control of dengue hemorrhagic fever. Kaohsiung J Med Sci 1994; 10 : 15-18.
[32] Lim LH. Research on dengue vector. Kaohsiung J Med Sci 1994; 10 :116-119.
[33] Chunsuttiwat S, Wasakarawa S. Dengue vector control in Thailand: development towards environmental protection. Kaohsiung J Med Sci 1994; 10 : 122-123.
[34]WHO. Dengue hemorrhagic fever: diagnosis, treatment and control. Geneva:1986:1-2.
[35] Ministry of Health, Malaysia. Vector borne disease control program. Kaohsiung J Med Sci 1994;10 : 113-115.
[36] Dominguez NN. National dengue prevention and control program in the Philippines.Kaohsiung J Med Sci 1994; 10: 118-121.
[37] Soedarmo SP. The epidemiology prevention and control of dengue hemorrhagic fever in Indonesia. Kaohsiung J Med Sci 1994; 10 : 109-112.
[38] Wang NC. Control of dengue vector in Singapore. Kaohsiung J Med Sci 1994; 10 133-38.
[39] Nguyen HT, et al. Dengue/dengue hemorrhagic fever situation in Vietnan. Kaohsiung J Med Sci 1994;10 : 124-130.
[40] Umenai T, Suzuki H. Review of the dengue/dengue hemorrhagic fever situation in the Western Pacific Region. Dengue Newsletter 1987; 13 : 69.
[41] Do M, et al. Epidemiology of dengue hemorrhagic fever in Vietnan during 1975-1983. Dengue Newsletter 1985;11 : 89.
[42] WHO. Dengue and dengue haemorrhagic fever. South-East Asia Region.Wkly Epidem Rec 1986; 61(27) : 205.
[43] Ungchusak K, Kunasol P. DHF in Thailand: The worsening situation in 30 years. Dengue Newsletter 1987; 13: 63.
[44] WHO. Report of the Consultation. Key issues in dengue vector control toward operationalization of a global strategy.Geneva:1995:1.
[45]沈海令,赵志梅,金东虎等.比翼线虫肺内感染3例[J].延边大学医学院学报,1998;21(2):122
[46]孙成斋.肝吸虫病[J].沈阳药科大学学报,沈阳:科学技术出版社,1985,12:16
[47]卫生部卫生防疫司寄生虫病处.我国主要寄生虫病防治现状[J],1992:32
[48]李秉正.华支睾吸虫与华支睾吸虫病[M].辽宁:沈阳出版社,1997,1:78
[49]华湘津.华支睾吸虫病诊断研究进展[J],中国寄生虫学与寄生虫病杂志,1994,12(1).
[50]桂爱芳.快速滤纸干血—ELISA诊断华支睾吸虫病的价值[J],中国人兽共患病杂志,1993,9(6):48.
[51]宁安等.华支睾吸虫病防治措施的研究[J].中国寄生虫病防治杂志,1994,7(4):52.
[52]胡秀荣、顾建明、陈林深、皇甫永令等.伊维菌素(1vermectin)晶体结构的研究[J].药学学报.1998.33(6):449-452
[53]杨明瑾.伊维菌素对大白鼠的长期毒性试验的研究[J].浙江省医学科学院学报,2000,6:45
[54]李明成.伊维菌素类药物的耐药性[J].黑龙江畜牧兽医.2001,9:19
[55]刘群.紫外分光光度法测定伊维菌素预混剂的含量.兽药与饲料添加剂.2001,6:15-18
[56]雷荣.高效液相色谱—串联质谱法鉴定伊维菌素的成分.分析化学研究报告.2002,1:29-32
[57]李毅斌.绵羊注射伊维菌素的中毒与治疗.动物科学与动物医学.2003,2,20(2):35
[58]徐慧斌,沈杰,叶明忠等.阿维菌素长效控释丸在绵羊体内的药物动力学研究[J].中国兽医寄生虫病杂志.1996,4(2):4-7
[59]王颜军.伊维菌素0.2%预混剂治疗蛋鸡皮刺螨效果观察[J].中国兽医杂志,2002,3:27
[60]冯克清.高效液相色谱法测定芬苯达唑原料中的有关物质[J].中国兽药杂志,2004,38(11):19-21
[61]许正敏.芬苯达唑、氟苯达唑和阿苯达唑对隐藏管状线虫作用的观察[J].中国寄生虫病防治杂志Chinese Journal of Parasitic D isease Control 1998;l1(1)
[62]李福荣.吡喹酮脂质体、吡喹酮、阿苯哒唑、氟苯哒唑和甲苯哒唑对胞球蚴病的疗效观察[J].中国寄生虫防治杂志,1995,8(1):39
[63]杨光友.丙硫苯咪唑和吡喹酮对鸭人工感染台湾次睾吸虫的驱除试验[J].中国兽医杂志,2004,3:15-16
[64]任丽君.伊维菌素缓释注射液的制备、含量测定及药代动力学[J].新缰医科大学硕士学位论文,2003:45-48
[65]郭虹,陈观今,郑焕钦等.弓形虫ROPI真核表达重组质粒DNA免疫小鼠后的免疫应答[J].中国寄生虫病与寄生虫病杂志,1999,175001-5004.
[66]杨维平,吴中兴.人体寄生虫病化学药物防治[M].南京:东南大学出版社,2004,
[67]冯忠武.我国兽药行业发展的现状及展望[J].中国兽药杂志,2004,38(3):1-6.
[68]莫云.简析跨国企业的兽药产品及市场特点[J].中国动物保健,2003,10:40-42.
[69]严晓岗.伊维菌素一般药理实验[J],浙江省医学院学报,2003,3:45
[70]刘明春.伊维菌素研究进展及其在我国兽医临床中的应用[J],辽宁畜牧畜医,2001,8:12
[71]张宏伟/杨廷桂主编,动物寄生虫病[M].中国农业出版社,2006,2:195
[72]沈继龙主编.医学寄生虫学[M].北京:中国医药科技出版社,1992,2:216
[73]古钦民主编.人体寄生虫学[M].青岛:青岛海洋大学出版社,1996,3:214
[74]詹希美主编.人体寄生虫学[M].第五版.北京:人民卫生出版社,2001,3:56
[75]詹希美主编.人体寄生虫学[M].北京:人民卫生出版社,2001,1:98
[76]陈兴保主编.现代寄生虫病学[M].北京:人民军医出版社,2002,1:105
[77]殷国荣主编.医学寄生虫学[M].双语教学版.北京:科学出版社,2004,1:563